# The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

> **NCT04206787** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 72 (actual)

## Conditions studied

- Non-squamous, Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT04206787
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-20
- **Primary completion:** 2023-12-18
- **Final completion:** 2023-12-22
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04206787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04206787, "The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT04206787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*